Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adoptive cell transfer therapy.

Mark E Dudley1, Steven A Rosenberg

  • 1Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1502, USA. Mark_Dudley@nih.gov

Seminars in Oncology
|December 18, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes.

Frontiers in immunology·2023
Same author

Barriers to referral and evaluation and corresponding navigation services for toddlers screening positive for autism spectrum disorder.

Families, systems & health : the journal of collaborative family healthcare·2023
Same author

Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens.

Cancer immunology, immunotherapy : CII·2023
Same author

Cell surface marker-based capture of neoantigen-reactive CD8<sup>+</sup> T-cell receptors from metastatic tumor digests.

Journal for immunotherapy of cancer·2023
Same author

Specific recognition of an <i>FGFR2</i> fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma.

Journal for immunotherapy of cancer·2023
Same author

Adoptive cell transfer immunotherapy for patients with solid epithelial cancers.

Cancer cell·2023
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Adoptive cell transfer therapy shows promise for metastatic melanoma by using engineered or natural tumor-infiltrating lymphocytes. Further research aims to enhance cell generation and administration for improved patient outcomes and broader applicability.

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular Therapy

Background:

  • Adoptive cell transfer (ACT) is a potent treatment for metastatic melanoma.
  • Current ACT methods involve ex vivo generation of tumor-reactive lymphocytes or genetic engineering for specific antigen recognition.

Purpose of the Study:

  • To improve methods for generating and administering ACT lymphocyte cultures.
  • To enhance durable response rates and expand patient eligibility for ACT therapy.

Main Methods:

  • Ex vivo generation of tumor-infiltrating lymphocytes (TILs).
  • Genetic engineering of lymphocytes with antigen receptor genes.
  • Administration of autologous anti-tumor lymphocyte cultures with high-dose interleukin-2 and lymphodepleting conditioning.

Related Experiment Videos

Main Results:

  • ACT therapy mediates tumor regression and durable clinical responses in patients.
  • In vivo expansion, tumor trafficking, and anti-tumor activity of administered lymphocytes.

Conclusions:

  • ACT is an effective immunotherapy for metastatic melanoma.
  • Ongoing research focuses on optimizing ACT protocols for better efficacy and wider patient application.